These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 24058588)
1. Preclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastases. Portella L; Vitale R; De Luca S; D'Alterio C; Ieranò C; Napolitano M; Riccio A; Polimeno MN; Monfregola L; Barbieri A; Luciano A; Ciarmiello A; Arra C; Castello G; Amodeo P; Scala S PLoS One; 2013; 8(9):e74548. PubMed ID: 24058588 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Kim SY; Lee CH; Midura BV; Yeung C; Mendoza A; Hong SH; Ren L; Wong D; Korz W; Merzouk A; Salari H; Zhang H; Hwang ST; Khanna C; Helman LJ Clin Exp Metastasis; 2008; 25(3):201-11. PubMed ID: 18071913 [TBL] [Abstract][Full Text] [Related]
3. Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases. Lee CH; Kakinuma T; Wang J; Zhang H; Palmer DC; Restifo NP; Hwang ST Mol Cancer Ther; 2006 Oct; 5(10):2592-9. PubMed ID: 17041104 [TBL] [Abstract][Full Text] [Related]
4. Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models. Peng SB; Zhang X; Paul D; Kays LM; Gough W; Stewart J; Uhlik MT; Chen Q; Hui YH; Zamek-Gliszczynski MJ; Wijsman JA; Credille KM; Yan LZ Mol Cancer Ther; 2015 Feb; 14(2):480-90. PubMed ID: 25504752 [TBL] [Abstract][Full Text] [Related]
5. Exploring the N-Terminal Region of C-X-C Motif Chemokine 12 (CXCL12): Identification of Plasma-Stable Cyclic Peptides As Novel, Potent C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonists. Di Maro S; Trotta AM; Brancaccio D; Di Leva FS; La Pietra V; Ieranò C; Napolitano M; Portella L; D'Alterio C; Siciliano RA; Sementa D; Tomassi S; Carotenuto A; Novellino E; Scala S; Marinelli L J Med Chem; 2016 Sep; 59(18):8369-80. PubMed ID: 27571038 [TBL] [Abstract][Full Text] [Related]
6. CXCR4 antibody treatment suppresses metastatic spread to the lung of intratibial human osteosarcoma xenografts in mice. Brennecke P; Arlt MJ; Campanile C; Husmann K; Gvozdenovic A; Apuzzo T; Thelen M; Born W; Fuchs B Clin Exp Metastasis; 2014 Mar; 31(3):339-49. PubMed ID: 24390633 [TBL] [Abstract][Full Text] [Related]
7. CXCL12 loaded-dermal filler captures CXCR4 expressing melanoma circulating tumor cells. Ieranò C; D'Alterio C; Giarra S; Napolitano M; Rea G; Portella L; Santagata A; Trotta AM; Barbieri A; Campani V; Luciano A; Arra C; Anniciello AM; Botti G; Mayol L; De Rosa G; Pacelli R; Scala S Cell Death Dis; 2019 Jul; 10(8):562. PubMed ID: 31332163 [TBL] [Abstract][Full Text] [Related]
8. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Murakami T; Maki W; Cardones AR; Fang H; Tun Kyi A; Nestle FO; Hwang ST Cancer Res; 2002 Dec; 62(24):7328-34. PubMed ID: 12499276 [TBL] [Abstract][Full Text] [Related]
9. Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells. Heinrich EL; Lee W; Lu J; Lowy AM; Kim J J Transl Med; 2012 Apr; 10():68. PubMed ID: 22472349 [TBL] [Abstract][Full Text] [Related]
10. CXCR4-antagonist Peptide R-liposomes for combined therapy against lung metastasis. Ieranò C; Portella L; Lusa S; Salzano G; D'Alterio C; Napolitano M; Buoncervello M; Macchia D; Spada M; Barbieri A; Luciano A; Barone MV; Gabriele L; Caraglia M; Arra C; De Rosa G; Scala S Nanoscale; 2016 Apr; 8(14):7562-71. PubMed ID: 26983756 [TBL] [Abstract][Full Text] [Related]
11. CXCR4 enhances adhesion of B16 tumor cells to endothelial cells in vitro and in vivo via beta(1) integrin. Cardones AR; Murakami T; Hwang ST Cancer Res; 2003 Oct; 63(20):6751-7. PubMed ID: 14583470 [TBL] [Abstract][Full Text] [Related]
12. Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists. Morimoto M; Matsuo Y; Koide S; Tsuboi K; Shamoto T; Sato T; Saito K; Takahashi H; Takeyama H BMC Cancer; 2016 May; 16():305. PubMed ID: 27175473 [TBL] [Abstract][Full Text] [Related]
13. Altered CXCL12 expression reveals a dual role of CXCR4 in osteosarcoma primary tumor growth and metastasis. Neklyudova O; Arlt MJ; Brennecke P; Thelen M; Gvozdenovic A; Kuzmanov A; Robl B; Botter SM; Born W; Fuchs B J Cancer Res Clin Oncol; 2016 Aug; 142(8):1739-50. PubMed ID: 27300512 [TBL] [Abstract][Full Text] [Related]
14. AMD3100 reduces CXCR4-mediated survival and metastasis of osteosarcoma by inhibiting JNK and Akt, but not p38 or Erk1/2, pathways in in vitro and mouse experiments. Liao YX; Fu ZZ; Zhou CH; Shan LC; Wang ZY; Yin F; Zheng LP; Hua YQ; Cai ZD Oncol Rep; 2015 Jul; 34(1):33-42. PubMed ID: 25997540 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of stromal CXCR4 impairs development of lung metastases. D'Alterio C; Barbieri A; Portella L; Palma G; Polimeno M; Riccio A; Ieranò C; Franco R; Scognamiglio G; Bryce J; Luciano A; Rea D; Arra C; Scala S Cancer Immunol Immunother; 2012 Oct; 61(10):1713-20. PubMed ID: 22399057 [TBL] [Abstract][Full Text] [Related]